Features Screener Stocks Charts
Sign In Sign Up

Piramal Enterprises Cash Flow Statement

NSE:PEL | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

-12.55x

PEL's operating cash flow was significantly below net income in FY 2025, suggesting earnings include substantial non-cash items.

Free Cash Flow

₹-83.65B

PEL's free cash flow was negative at ₹-83.65B in FY 2025, down 572.8% from FY 2024. The company spent more on capital investments than it generated from operations.

Dividend Coverage

-37.2x

PEL's free cash flow did not fully cover dividends in FY 2025. The company may be funding dividends from reserves or borrowings.

2-year PEL cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income -13.46B 6.45B
Cash flow Operating Activities 264.30M -80.91B
Investments in PPE -12.70B -2.74B
Cash flow Investing Activities -18.72B -18.54B
Dividend Paid -7.40B -2.25B
Cash flow Financing Activities 13.90B 116.64B
Cash at beginning of period 37.29B 32.74B
Cash at end of period 32.74B 49.92B
Free Cash Flow -12.43B -83.65B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025